Metagenomi, Inc. Common Stock (MGX) Financials

MGX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 173.7 million 61.1 million
March 31, 2026 197.0 million 59.2 million
Dec. 31, 2025 221.1 million 62.5 million
Sept. 30, 2025 247.9 million 69.5 million

MGX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -19.6 million 2.3 million
March 31, 2026 -21.2 million 2.6 million
Dec. 31, 2025 -23.6 million 2.7 million
Sept. 30, 2025 -21.3 million 3.0 million

MGX Net Income

No data available :(

MGX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 120.7 million - 31.5 million
March 31, 2026 140.2 million - 39.2 million
Dec. 31, 2025 160.8 million - 40.7 million
Sept. 30, 2025 184.1 million - 41.7 million

MGX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 37.7 million
March 31, 2026 37.6 million
Dec. 31, 2025 37.6 million
Sept. 30, 2025 37.3 million

MGX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 125000 22.5 million 6.0 million -
March 31, 2026 25000 19.3 million 6.5 million -
Dec. 31, 2025 85000 21.5 million 5.5 million -
Sept. 30, 2025 74000 24.0 million 6.2 million -

MGX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 -257000 -
March 31, 2026 1.2 million 863000
Dec. 31, 2025 3.9 million 1.3 million
Sept. 30, 2025 8.7 million 1.3 million

MGX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

MGX

Price: $1.23

52 week price:
1.13
3.95

Earnings Per Share: -2.55 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 46.5 million

Links: